Skip to content
Who We Serve
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees
About Us
Our Team
Our Story
Investment Strategies
Who We Serve
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees
About Us
Our Team
Our Story
Investment Strategies
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees (911 Financial Services™)
Our Story
Our Team
Investment Strategies
Contact Us
Schwab Client Login
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees (911 Financial Services™)
Our Story
Our Team
Investment Strategies
Contact Us
Schwab Client Login
Contact Us
Schwab Client Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
REGENXBIO Inc. - Common Stock
(NQ:
RGNX
)
6.680
-0.490 (-6.83%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 23, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about REGENXBIO Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
REGENXBIO Eyes Q4 Pivotal Readout for One-Time Wet AMD Gene Therapy
↗
October 21, 2026
REGENXBIO (NASDAQ:RGNX) outlined its clinical, manufacturing and commercialization plans for sura-vec, an investigational one-time subretinal gene therapy for wet age-related macular degeneration, or...
Via
MarketBeat
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of REGENXBIO Inc. (RGNX)
August 25, 2026
From
Johnson Fistel, PLLP
Via
Business Wire
Top movers in Monday's session
↗
August 24, 2026
Via
Chartmill
Which stocks are experiencing notable movement on Monday?
↗
August 24, 2026
Via
Chartmill
REGENXBIO (NASDAQ:RGNX) Beats Q2 EPS but Misses Revenue; Duchenne Gene Therapy Timeline Reaffirmed
↗
August 06, 2026
Via
Chartmill
REGENXBIO INC (NASDAQ:RGNX) Plunges 17% on Q1 Revenue Miss Despite Positive DMD Gene Therapy Trial Results
↗
May 14, 2026
Via
Chartmill
Monday's session: gap up and gap down stocks
↗
August 24, 2026
Via
Chartmill
Monday's pre-market session: top gainers and losers
↗
August 24, 2026
Via
Chartmill
REGENXBIO Q2 Earnings Call Highlights
↗
August 07, 2026
REGENXBIO (NASDAQ:RGNX) reported second-quarter 2026 progress across its late-stage gene-therapy pipeline, highlighting completed enrollment in its Duchenne muscular dystrophy confirmatory study, an...
Via
MarketBeat
Topics
Earnings
The market is filled with gapping stocks in Friday's session.
↗
July 17, 2026
Via
Chartmill
What's going on in today's pre-market session
↗
July 17, 2026
Via
Chartmill
Thursday's after hours session: top gainers and losers
↗
July 16, 2026
Via
Chartmill
Regenxbio (RGNX) Q1 2026 Earnings Transcript
↗
May 18, 2026
Regenxbio (RGNX) Q1 2026 Earnings Transcript
Via
The Motley Fool
These stocks are moving in today's session
↗
May 14, 2026
Via
Chartmill
What's going on in today's session
↗
May 14, 2026
Via
Chartmill
Which stocks are gapping on Thursday?
↗
May 14, 2026
Via
Chartmill
Discover the top movers in Thursday's pre-market session.
↗
May 14, 2026
Via
Chartmill
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNX
April 14, 2026
From
Pomerantz LLP
Via
GlobeNewswire
RGNX Deadline Today: Rosen Law Firm Urges REGENXBIO, Inc. (NASDAQ: RGNX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
April 14, 2026
From
The Rosen Law Firm, P.A.
Via
Business Wire
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of the Securities Class Action Lawsuit Deadline on April 14, 2026
April 14, 2026
From
Faruqi & Faruqi, LLP
Via
Business Wire
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
April 13, 2026
From
Schall Law
Via
GlobeNewswire
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
April 09, 2026
From
Schall Law
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNX
April 07, 2026
From
Pomerantz LLP
Via
GlobeNewswire
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
April 06, 2026
From
Schall Law
Via
GlobeNewswire
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX
April 05, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
ROSEN, SKILLED INVESTOR COUNSEL, Encourages REGENXBIO, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RGNX
April 04, 2026
From
The Rosen Law Firm PA
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PayPal and REGENXBIO and Encourages Investors to Contact the Firm
April 03, 2026
From
Bragar Eagel & Squire
Via
GlobeNewswire
RGNX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026
April 02, 2026
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm
April 02, 2026
From
Schall Law
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines – RGNX
March 31, 2026
From
Pomerantz LLP
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
